News

Robert L. Stamper, MD, discusses some of the devices in development for measuring patients' intraocular pressure outside of doctors' office hours in his presentation at Glaucoma Research Foundation's annual Glaucoma Symposium.

L. Jay Katz, MD, provides some key takeaways from his Glaucoma 360 2023 presentation, "Steroid Induced Glaucoma Management."

Shan C. Lin, MD, provides an overview of the various intraocular lens technologies that are available, as well as considerations for contrast sensitivity and vision loss in patients at Glaucoma Research Foundation's annual Glaucoma Symposium.

Ying Han, MD, PhD, provides some key takeaways from her Glaucoma 360 2023 presentation, "Tube shunt update."

Thurein Htoo, MS, MBA, CEO and co-founder of Qlaris Bio, took the podium at the New Horizons Forum at the Glaucoma 360 conference in San Francisco to discuss the performance of the company’s episcleral venous pressure eyedrop, QLS-111.

Kristen H. Ingenito, MBA, vice president and director of ophthalmics at Market Scope, discusses the volume of ophthalmologists offering interventional glaucoma treatment as well as emerging therapies in her presentation at the Glaucoma 360 New Horizons Forum.

The Phase 2 SPECTRA clinical trial will assess 4D-150 in patients with DME.

According to the indictment, beginning in June 2017, Anthony David Flores and Anna Rene Moore used false promises and representations to befriend the victim — an ophthalmologist and successful investor worth more than $60 million.

The results are consistent with those observed, and previously published by the same group, showing benefit in age related macular degeneration models and highlights the potential value of ophNdi1 for multiple eye diseases.

The company noted that the product is a sterile, single-patient use, physician administered, ophthalmic gel preparation, containing no preservatives, that is safe and effective for ocular surface anesthesia.

The vision care company is joining forces with the global nonprofit to fight avoidable blindness around the world.

According to the company, ONL1204 is a first-in-class small molecule Fas inhibitor with a mechanism of action designed to provide neuroprotection for retinal cells.

Bausch + Lomb and Modulight announce the photodynamic laser for use with photodynamic therapy was approved by the FDA for the treatment of patients with subfoveal choroidal neovascularization due to AMD.

The Bascom Palmer program showcases neovascular, exudative, and degenerative eye diseases, and is designed for retina specialists, general ophthalmologists and researchers.

In a news release, the CDC is urging that clinicians and patients immediately discontinue the use of EzriCare Artificial Tears until the epidemiological investigation and laboratory analyses are complete.

A leader in the field of ophthalmology, Cynthia Matossian, MD, FACS, ABES, discusses her career as she prepares for the next phase.

Effective networking involves developing relationships with other people, sharing relevant information and resources, and providing mutual support and encouragement on the path to reaching your goals.

According to the company, the approval allows Eyenuk’s EyeArt AI eye screening system, already approved for detection of diabetic retinopathy, to aid millions of additional patients at risk for vision loss.

With donations, the West Virginia University Department of Ophthalmology and Visual Sciences has added two new pieces of ophthalmic training equipment to its lab.

Specialists seek more information for use in the treatment of patients diagnosed with retinal diseases

Physicians explain how winter exacerbates symptoms of disease.

HG004 aims to be more effective than other AAV2 products in treatment of inherited retinal diseases caused by mutations in the RPE65 gene.

The workshop is designed to bring together leading experts from academia and industry, to discuss openly, and in detail, what is known about PRPH2 disease pathology, disease models, clinical characteristics, and therapeutic approaches.

Minimally invasive, novel system achieves significant pressure level reductions.

Patients diagnosed with diabetic retinopathy may be particularly vulnerable to periods of low glucose, and keeping glucose levels stable should be an important part of glucose control.

Tailored approach can help physicians provide better outcomes for patients

The technique could provide researchers with samples for studying AMD and other eye diseases.

In preclinical models, investigators at Brigham and Women’s Hospital uncovered a novel mechanism underlying the development of diabetic cataracts that undermines current hypothesis